IE921534A1 - Novel composition of angiotensin-ii receptor antagonists and¹calcium channel blockers - Google Patents
Novel composition of angiotensin-ii receptor antagonists and¹calcium channel blockersInfo
- Publication number
- IE921534A1 IE921534A1 IE153492A IE921534A IE921534A1 IE 921534 A1 IE921534 A1 IE 921534A1 IE 153492 A IE153492 A IE 153492A IE 921534 A IE921534 A IE 921534A IE 921534 A1 IE921534 A1 IE 921534A1
- Authority
- IE
- Ireland
- Prior art keywords
- tetrazol
- imidazole
- methyl
- propyl
- carbon atoms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Novel pharmaceutical compositions containing a combination of an angiotensin-II antagonist and a calcium channel blocker such as 2-butyl-4 chloro-1-[2-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxymethyl) imidazole, and diltiazem and the use of such compositions in the treatment of hypertension and congestive heart failure.
Description
Description
NOVEL COMPOSITION OF ANGIOTENSIN-II RECEPTOR ANTAGONISTS AND CALCIUM CHANNEL BLOCKERS
Summary of the Invention
This invention relates to novel pharmaceutical compositions containing an angiotensin-II receptor antagonist from a selected class in combination with a calcium channel blocker from a selected class useful for
0 the treatment of hypertension and for the treatment of congestive heart failure.
Background of the Invention The selected class of angiotensin-II receptor
antagonists and the selected class of calcium channel blockers essential as component parts of the novel compositions of this invention are compounds already known in the art as antihypertensive agents.
✓
Angiotensin-II receptor antagonists useful in compositions of the invention are included in those compounds disclosed in published European Published application 0 324 377 the disclosure of which is incorporated herein by reference.
Calcium channel blockers useful in the compositions of this invention are selected from the group consisting of diltiazem, nifedipine, nitrendipine, nimodipine, niludipine, niguldipine, nicardipine, nisoldipine, amlodipine, felodipine, isradipine, ryosidine, verapamil, gallopamil and tiapamil.
Detailed Description of the Invention The novel compositions of this invention contain a calcium channel blocker of the group defined above in combination with an angiotensin-II receptor antagonist compound of the following formula:
R4
wherein
R1 is CO2H; NHSO2CF3 and
N—N
H
R2 is H, alkyl of 1 to 4 carbon atoms, halogen, or 10 alkoxy of 1 to 4 carbon atoms;
R3 is alkyl, alkenyl or alkynyl of 3 to 7 carbon atoms;
R4 is H, Cl, Br, I; alkyl of 1 to 4 carbon atoms;
0
II
CvF2v+l» where v=l-3; or -CR6;
R5 is -(CH2)mOR7; -(CH2)ffiOCR7; -CH-CH-CHOR8 ; -(CH2)jnCR6
I
R7
-CH2NHCOR9; - (CH2) mNHSO2R9;
w
H ; or -COR6;
R6 is H, alkyl of 1 to 5 carbon atoms or OR10;
R7 is H or alkyl of 1 to 4 carbon atoms;
R® is H, alkyl of 1 to 4 carbon atoms, or acyl of 1 to 4 carbon atoms;
R9 is CF3, alkyl of 1 to 6 carbon atoms or phenyl;
R10 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of to 6 carbon atoms, phenyl or benzyl;
m is 1 to 5 or a pharmaceutically acceptable salt thereof.
Preferred compounds of the· above formula are those 15 in which R1 is
and R2 is H. Illustrative compounds of this preferred scop·, are :
· 2-butyl-4-chloro-l-[(2'(lH-tetrazol-5-yl)biphenyl4-yl)methyl]-5-(hydroxymethyl)imidazole 2-butyl-4-chloro-l-[(2'-(lH-tetrazol-5yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid propyl-4-trifluoromethyl-l-[(2’-(lH-tetrazol-5yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid • 2 propyl-4-chloro-l-(2(lH-tetrazol-5yl)biphenyl-4-yl)methyl]imidazole-5-carboxaldehyde • 2 propyl-4-ethyl-1-I(2'(lH-tetrazol-5-yl)biphenyl4-yl)methyl]imidazole-5-carboxylic acid · 2 propyl-4-ethyl-l-[(2’-lH-tetrazol-5-yl)biphenyl4-yl)methyl]imidazole-5-carboxaldehyde • 2-propyl-4-pentafluoroethyl-l-[(2'-(lH-tetrazol-5yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid · 2-propyl-4-chloro-l-[2'-(lH-tetrazol-5yl,biphenyl-4-yl)methyl]imidazole-5-carboxylic acid.
The potential antihypertensive effects of the combination of compounds of this invention may be demonstrated by administering the combination of active *
compounds to conscious spontaneously hypertensive rats. Rats received either orally or intravenously a dose of 0.1-30 mg/kg of the desired calcium channel blocker, or a dose of 0.1-30 mg/kg of the desired angiotensin-II receptor antagonist, or a combination of the two doses of the calcium channel blocker and the angiotensin-II receptor antagonist. Arterial blood pressure is continuously measured directly through a carotid artery catheter and recorded using a pressure transducer and a polygraph. Blood pressure levels after treatment are compared to pretreatment levels.
The combination of active compounds of this invention are unexpectedly useful in treating
0 hypertension. They are also of value in the management of acute and chronic congestive heart failure. These combinations also be expected to be useful in the treatment of secondary hyperaldosteronism, primary and secondary pulmonary hyperaldosteronism, primary and secondary pulmonary hypertension, renal failure such as diabetic nephropathy, glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, end stage renal disease, renal transplant therapy, and the like, renal vascular hypertension, left ventricular dysfunction, diabetic retinopathy and in the management of vascular disorders such as migraine, Raynaud's disease, luminal hyperplasia, and to minimize the atherosclerotic process.
The combinations of this invention can be administered for the treatment of hypertension according to the invention by any means that effects contact of the active ingredient compounds with the site of action in the body of a warm-blooded animal in need of such treatment. For example, administration can be parenteral, i.e., subcutaneous, intravenous, intramuscular, or intra peritoneal. Alternatively, or concurrently, in some cases administration can be by the oral route.
The combinations of compounds can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination with additional therapeutic agents. For example the combination of this invention of an angiotensin-II antagonist and calcium channel blocker can be combined with other antihypertensives and/or diuretics and/or angiotensin converting enzyme inhibitors such as amiloride, atenolol, bendroflumethiazide, chlorothalidone, chlorothiazide, clonidine, cryptenamine acetates and cryptenamine tannates, deserpidine, diazoxide, guanethidene sulfate, hydralazine hydrochloride, hydrochlorothiazide, metolazone, metoprolol tartate, methyclothiazide, methyldopa, methyldopate hydrochloride, minoxidil, pargyline hydrochloride, polythiazide, prazosin, propranolol, rauwolfia serpentina, rescinnamine, reserpine, sodium nitroprusside, spironolactone, timolol maleate, trichlormethiazide, trimethophan camsylate, benzthiazide, quinethazone, ticrynafan, triamterene, acetazolamide, aminophylline, cyclothiazide, ethacrynic acid, furosemide, merethoxylline procaine, sodium ethacrynate, captopril, delapril hydrochloride, enalapril, enalaprilat, fosinopril sodium, lisinopril, pentopril, quinapril hydrochloride, ramapril, teprotide, zofenopril calcium, diflusinal and the like.
The combinations of active compounds can be administered alone, but are generally administered with *
a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
For the purpose of this disclosure, a warm-blooded animal is a member of the animal kingdom possessed of a homeostatic mechanism and includes mammals and birds.
Pharmaceutical compositions of the invention may contain from 10 to 300 mg of the desired calcium channel blocker and 1 to 100 mg of the angiotensin-II receptor antagonist per unit dose one or more times daily.
The active ingredients can be administered orally in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs
0 syrups, and suspensions. They can also be administered parenterally, in sterile liquid dosage forms.
Gelatin capsules contain the active ingredients and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours.
Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance .
In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and 1 5 glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions.
Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer 20 substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents.
Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain 25 preservatives, such as benzalkonium chloride, methyl- or propylparaben, and chlorobutanol.
Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences. A. Osol, a standard reference text in this field.
Useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows:
β
Capsules
A large number of unit capsules are prepared by filling standard two-piece hard gelatin capsules each as with 100 milligrams of powdered active ingredients, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate.
Soft Gelatin Capsules
A mixture of active ingredients in a digestible oil 10 such as.soybean oil, cottonseed oil or olive oil is combinations prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredients. The capsules are washed and dried.
Tablets
A large number of tablets* are prepared by conventional procedures so that the dosage unit is 100 milligrams of active ingredients, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or delay absorption.
Injectable
A parenteral composition suitable for administration by injection is prepared by stirring 1.5% by weight of active ingredients in 10% by volume
0 propylene glycol. The solution is made to volume with water for injection and sterilized.
s
Suspension
An aqueous suspension is prepared for oral administration so that each 5 milliliters contain 100 milligrams of finely divided active ingredients, 100 milligrams of sodium carboxymethyl cellulose, 5 milligrams of sodium benzoate, 1.0 grams of sorbitol solution, U.S.P., and 0.025 milliliters of vanillin.
Claims (2)
1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a combination of an angiotensin-II receptor antagonist compound of the formula: R 2 wherein R 1 is CO2H; NHSO2CF3 and N—N '/ * R 2 is H, alkyl of 1 to 4 carbon atoms, halogen, or alkoxy of 1 to 4 carbon atoms; R 3 is alkyl, alkenyl or alkynyl of 3 to 7 carbon atoms; R 4 is H, Cl, Br, I; alkyl of 1 to 4 carbon atoms; C v F2v+ir where v=l-3; or -CR 6 ; V» R 5 is -(CH2)mOR 7 ; -(CH2) m OCR 7 ; -CH-CH-CHOR 8 ; -(CH 2 ),nCR 6 j R 7 -CH 2 NHCOR 9 ; - (CH 2 )ntNHSO 2 R 9 / If N—N H ; or -COR 6 ; R 6 is H, alkyl of 1 to 5 carbon atoms or OR 10 ; R 7 is H or alkyl of 1 to 4 carbon atoms; R 8 is H, alkyl of 1 to 4 carbon atoms, or acyl of 1 to 10 4 carbon atoms; R 9 is CF3, alkyl of 1 to 6 carbon atoms or phenyl; R 10 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl; m is 1 to 5 or a pharmaceutically acceptable salt thereof and a calcium channel blocker compound selected from the group consisting of: diltiazem, nifedipine, nitrendipine, nimodipine, niludipine, niguldipine, nicardipine, 20 nisoldipine, amlodipine, felodipine, isradipine, ryosidine, verapamil, gallopamil and tiapamil. 2. The composition of Claim 1 wherein the angiotensin-II receptor antagonist is selected 2 5 from the group consisting of: 2-butyl-4-chloro-l- I (2 1 (lH-tetrazol-5-yl)biphenyl4-yl) methyl]-5-(hydroxymethyl) imidazole 2-butyl-4-chloro-l-[(2(lH-tetrazol-5yl) biphenyl-4-yl) methyl ] imidazole-5-carboxylic acid 10 · 2 propyl-4-trifluoromethyl-1-[(2*-(lH-tetrazol-5yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid 2 propyl-4-chloro-1-[2'-{lH-tetrazol-5yl)bipheny1-4-yl)methyl]imidazole-5-carboxaldehyde 2 propyl-4-ethyl-1-[(2’(lH-tetrazol-5-yl)biphenyl4-yl)methyl]imidazole-5-carboxylic acid 2 propyl-4-ethyl-l-[(2'-lH-tetrazol-5-yl)biphenyl4-yl)methyl]imidazole-5-carboxaldehyde 2-propyl-4-pentafluoroethyl-1-[ (2 ’ -(lH-tetrazol-5yl)bipheny1-4-yl)methy1]imidazole-5-carboxylic acid 2-propyl-4-chloro-l-[2’-(lH-tetrazol-5yl)bipheny1-4-yl) methyl]imidazole-5-carboxylic acid. The composition of Claim 2 wherein the calcium channel blocker is diltiazem. The composition of Claim 3 wherein the angiotensin-II receptor antagonist is 2-(butyl-4chloro-1-[2-(lH-tetrazol-5-yl)biphenyl-4yl)methyl]-5-(hydroxymethyl) imidazole. The composition of Claim 3 wherein the angiotensin-II receptor antagonist is 2-propyl-4pentafluoroethyl-1-[(2’-(lH-tetrazol-5y1) biphenyl-4-y1) methyl]imidazole-5-carboxyli c acid. A method of treating hypertension which comprises administering to a patient in need of such 15 · treatment a therapeutically effective amount of a composition of Claim 1. The method of Claim 6 wherein the angiotensin-II receptor antagonist is selected from the group consisting of: 2-butyl-4-chloro-l-[(2’(lH-tetrazol-5-yl)biphenyl4-yl) methyl]-5-(hydroxymethyl) imidazole 2-butyl-4-chloro-l-[(2'-(lH-tetrazol-5yl)bipheny1-4-yl) methyl]imidazole-5-carboxylic acid 2 propyl-4-trifluoromethyl-l-[(2'-(lH-tetrazol-5yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid 2 propyl-4-chloro-1-[2’-(lH-tetrazol-5yl)biphenyl-4-yl)methyl]imidazole-5-carboxaldehyde 2 propyl-4-ethyl-l-[ (2 ’ (l*H-tetrazol-5-yl) biphenyl4-yl) methyl]imidazole-5-carboxylic acid 2 propyl-4-ethyl-l-[(2’-lH-tetrazol-5-yl)biphenyl4-yl) methyl]imidazole-5-carboxaldehyd 2-propyl-4-pentafluoroethyl-l-[(2’-(lH-tetrazol-5yl)bipheny1-4-yl) methyl]imidazole-5-carboxylic acid
2. -propyl-4-chloro-1-[2’-(lH-tetrazol-5yl)bipheny1-4-yl) methyl]imidazole-5-carboxylic acid. The method of Claim 6 wherein the calcium channel blocker is diltiazem. The method of Claim 8 wherein the angiotensin receptor antagonist is 2-butyl-4-chloro-l-[2-(1H30
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70074091A | 1991-05-15 | 1991-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IE921534A1 true IE921534A1 (en) | 1992-11-18 |
Family
ID=24814683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE153492A IE921534A1 (en) | 1991-05-15 | 1992-07-01 | Novel composition of angiotensin-ii receptor antagonists and¹calcium channel blockers |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0584250A1 (en) |
| JP (1) | JP2930252B2 (en) |
| AU (1) | AU664375B2 (en) |
| CA (1) | CA2103276A1 (en) |
| CZ (1) | CZ281570B6 (en) |
| IE (1) | IE921534A1 (en) |
| IL (1) | IL101858A (en) |
| MX (1) | MX9202243A (en) |
| NZ (1) | NZ242724A (en) |
| WO (1) | WO1992020342A1 (en) |
| ZA (1) | ZA923557B (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3057471B2 (en) | 1993-06-07 | 2000-06-26 | 武田薬品工業株式会社 | Agent for preventing or treating angiotensin II-mediated diseases |
| JP3883205B2 (en) * | 1994-03-29 | 2007-02-21 | メルク エンド カンパニー インコーポレーテッド | Treatment of Atherosclerosis with Angiotensin II Receptor Blocking Imidazole |
| WO1996028185A2 (en) | 1995-03-16 | 1996-09-19 | Pfizer Inc. | Composition containing amlodipine, or a salt, or felodipine and an ace inhibitor |
| TR200100062T2 (en) | 1998-07-10 | 2001-06-21 | Novartis Ag | Anti-hypertensive combination of valsartan and calcium channel blocker |
| US6204281B1 (en) | 1998-07-10 | 2001-03-20 | Novartis Ag | Method of treatment and pharmaceutical composition |
| US7481803B2 (en) * | 2000-11-28 | 2009-01-27 | Flowmedica, Inc. | Intra-aortic renal drug delivery catheter |
| US6395728B2 (en) | 1999-07-08 | 2002-05-28 | Novartis Ag | Method of treatment and pharmaceutical composition |
| JP4000505B2 (en) | 1999-12-01 | 2007-10-31 | 第一三共株式会社 | Concomitant medications for treating glaucoma |
| GB0008332D0 (en) * | 2000-04-04 | 2000-05-24 | Pfizer Ltd | Treament |
| AU2001267404A1 (en) * | 2000-05-04 | 2001-11-12 | Ipf Pharmaceuticals Gmbh | Novel compounds for the treatment of inflammatory and cardiovascular diseases |
| WO2002043807A2 (en) * | 2000-12-01 | 2002-06-06 | Novartis Ag | Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction |
| EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| AU2004208615C1 (en) | 2003-01-31 | 2010-05-13 | Daiichi Sankyo Company, Limited | Medicine for prevention of and treatment for arteriosclerosis and hypertension |
| TW200833325A (en) * | 2006-12-26 | 2008-08-16 | Daiichi Sankyo Co Ltd | Pharmaceutical composition comprising ascorbic acid |
| ES2393885T7 (en) | 2007-06-04 | 2014-01-30 | Synergy Pharmaceuticals Inc. | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| ES2522968T3 (en) | 2008-06-04 | 2014-11-19 | Synergy Pharmaceuticals Inc. | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| JP2016514671A (en) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | Guanylate cyclase agonists and uses thereof |
| US10011637B2 (en) | 2013-06-05 | 2018-07-03 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2607004B1 (en) * | 1986-11-20 | 1990-06-01 | Synthelabo | PHARMACEUTICAL COMPOSITIONS CONTAINING DILTIAZEM AND AN ANGIOTENSIN CONVERSION ENZYME INHIBITOR |
| US5015651A (en) * | 1988-01-07 | 1991-05-14 | E. I. Du Pont De Nemours And Company | Treatment of hypertension with 1,2,4-angiotensin II antagonists |
| CA2020073A1 (en) * | 1989-07-03 | 1991-01-04 | Eric E. Allen | Substituted quinazolinones as angiotensin ii antagonists |
| EP0565634B1 (en) * | 1990-12-14 | 1999-03-17 | Smithkline Beecham Corporation | Angiotensin ii receptor blocking compositions |
-
1992
- 1992-05-13 NZ NZ242724A patent/NZ242724A/en not_active IP Right Cessation
- 1992-05-14 JP JP5500110A patent/JP2930252B2/en not_active Expired - Lifetime
- 1992-05-14 IL IL10185892A patent/IL101858A/en not_active IP Right Cessation
- 1992-05-14 CA CA002103276A patent/CA2103276A1/en not_active Abandoned
- 1992-05-14 CZ CS932351A patent/CZ281570B6/en not_active IP Right Cessation
- 1992-05-14 MX MX9202243A patent/MX9202243A/en unknown
- 1992-05-14 EP EP92912707A patent/EP0584250A1/en not_active Withdrawn
- 1992-05-14 WO PCT/US1992/003873 patent/WO1992020342A1/en not_active Application Discontinuation
- 1992-05-14 AU AU20269/92A patent/AU664375B2/en not_active Expired
- 1992-05-15 ZA ZA923557A patent/ZA923557B/en unknown
- 1992-07-01 IE IE153492A patent/IE921534A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JPH06508128A (en) | 1994-09-14 |
| EP0584250A4 (en) | 1994-03-30 |
| CZ281570B6 (en) | 1996-11-13 |
| ZA923557B (en) | 1993-11-15 |
| AU664375B2 (en) | 1995-11-16 |
| EP0584250A1 (en) | 1994-03-02 |
| NZ242724A (en) | 1994-09-27 |
| IL101858A (en) | 1996-08-04 |
| IL101858A0 (en) | 1992-12-30 |
| CA2103276A1 (en) | 1992-11-16 |
| WO1992020342A1 (en) | 1992-11-26 |
| MX9202243A (en) | 1992-11-01 |
| JP2930252B2 (en) | 1999-08-03 |
| AU2026992A (en) | 1992-12-30 |
| CZ235193A3 (en) | 1994-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU664375B2 (en) | Novel composition of angiotensin-II receptor antagonists and calcium channel blockers | |
| US5492904A (en) | Composition of angiotensin-II receptor antagonists and calcium channel blockers | |
| US5958961A (en) | Pharmaceutical composition for angiotensin II-mediated diseases | |
| US4873076A (en) | Method of safely providing anesthesia or conscious sedation | |
| EP0628313B1 (en) | Combination of an angiotensin-II antagonising benzimidazole with manidipine for the treatment of hypertension | |
| KR910007927A (en) | Condensed imidazole derivatives and preparation methods thereof | |
| HU219404B (en) | Process for producing pharmaceutical compositions containing angiotenzin-ii-receptor-blocking compounds for treating cardial and vascular hypertrofie and/or hyperplasy | |
| JPH05509086A (en) | Treatment of chronic renal failure with imidazole angiotensin-2 receptor antagonists | |
| US20050059720A1 (en) | Medicinal compositions for the prevention or treatment of cardiac failure | |
| ZA200105828B (en) | Medicament for treating hypertension. | |
| JP2002537258A5 (en) | ||
| IL98794A (en) | 4-alkyl-2-propyl-1-[(2'-(1h-tetrazol-5-yl) biphenyl-4-yl)-methyl]-imidazole derivatives and pharmaceutical compositions containing them | |
| WO2002041890A1 (en) | Medicinal compositions | |
| JP3057471B2 (en) | Agent for preventing or treating angiotensin II-mediated diseases | |
| EP0398326A2 (en) | Serotonin antagonist | |
| EP0368972B1 (en) | Method of safely providing anesthesia or conscious sedation | |
| EP0631780A1 (en) | Use of an angiotensin II antagonist as an ocular hypotensive agent | |
| EP0612523B1 (en) | Vascular hypertrophy suppressor | |
| KR100222627B1 (en) | Novel pharmaceutical composition of angiotensin-ii receptor antagonists and calcium channel blockers | |
| CA2459017A1 (en) | Medicinal compositions containing angiotensin ii receptor antagonist | |
| JP3639982B2 (en) | Easy-to-absorbable oral pharmaceutical composition of carboxymethylidenecycloheptimidazole derivative | |
| JPH01275529A (en) | Suppressing treatment agent of delayed motion effect | |
| GB2227664A (en) | Treating hypertension using a thromboxane A2 receptor antagonist | |
| JPH0344321A (en) | Remedy composition for anti-hypertension and anti-congestive heart failure | |
| MXPA01008164A (en) | Medicament for treating hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC9A | Application refused sect. 31(1) |